FIGURE 5.

Pevonedistat treatment inhibits NF-κB pathway. A, CLBL-1 cells were treated with DMSO or pevonedistat (0.1–0.7 μM) for 1, 4, 12, and 24 hours. Cell lysates were immunoblotted for p-IκBα. β-actin was used as a loading control. B, CLBL-1 cells were treated with IC₉₀ concentration (0.58 μM) of pevonedistat for 1, 3, 12 and 24 hours, NF-κB pathway target gene expressions were measured by qRT-PCR and were compared with the gene expression levels in cells treated with DMSO. Gene expression level in DMSO-treated cells were set as ddCt = 0. C, Canine primary DLBCL cells were treated with pevonedistat for 24 hours, and NF-κB pathway target gene expressions were compared with DMSO control. Gene expression level in DMSO-treated cells were set as ddCt = 0. Each lane represents one patient sample